IT1392356B1 - Procedimento di microincapsulamento di cellule del sertoli, microcapsule ottenute e loro impiego per la prevenzione e la cura del diabete mellito di tipo 1. - Google Patents

Procedimento di microincapsulamento di cellule del sertoli, microcapsule ottenute e loro impiego per la prevenzione e la cura del diabete mellito di tipo 1.

Info

Publication number
IT1392356B1
IT1392356B1 ITRM2008A000686A ITRM20080686A IT1392356B1 IT 1392356 B1 IT1392356 B1 IT 1392356B1 IT RM2008A000686 A ITRM2008A000686 A IT RM2008A000686A IT RM20080686 A ITRM20080686 A IT RM20080686A IT 1392356 B1 IT1392356 B1 IT 1392356B1
Authority
IT
Italy
Prior art keywords
microcapsulation
care
prevention
procedure
type
Prior art date
Application number
ITRM2008A000686A
Other languages
English (en)
Inventor
Massimo Menegazzo
Riccardo Calafiore
Francesca Fallarino
Paolo Puccetti
Giovanni Luca
Carlo Foresta
Daniela Zuccarello
Original Assignee
Università degli Studi di Perugia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ITRM2008A000686A priority Critical patent/IT1392356B1/it
Application filed by Università degli Studi di Perugia filed Critical Università degli Studi di Perugia
Priority to US13/140,728 priority patent/US8865218B2/en
Priority to CA2756091A priority patent/CA2756091C/en
Priority to NZ593507A priority patent/NZ593507A/xx
Priority to EP09807677.1A priority patent/EP2373299B1/en
Priority to AU2009329069A priority patent/AU2009329069B2/en
Priority to PCT/IB2009/055847 priority patent/WO2010070618A2/en
Priority to RU2011128262/15A priority patent/RU2598736C2/ru
Priority to CN200980151428.3A priority patent/CN102256601B/zh
Priority to JP2011541709A priority patent/JP5930279B2/ja
Priority to KR1020117016882A priority patent/KR101722476B1/ko
Publication of ITRM20080686A1 publication Critical patent/ITRM20080686A1/it
Priority to IL213617A priority patent/IL213617A/en
Application granted granted Critical
Publication of IT1392356B1 publication Critical patent/IT1392356B1/it
Priority to HK12104075.6A priority patent/HK1163517A1/xx
Priority to US14/513,893 priority patent/US20150044109A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ITRM2008A000686A 2008-12-19 2008-12-19 Procedimento di microincapsulamento di cellule del sertoli, microcapsule ottenute e loro impiego per la prevenzione e la cura del diabete mellito di tipo 1. IT1392356B1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ITRM2008A000686A IT1392356B1 (it) 2008-12-19 2008-12-19 Procedimento di microincapsulamento di cellule del sertoli, microcapsule ottenute e loro impiego per la prevenzione e la cura del diabete mellito di tipo 1.
CN200980151428.3A CN102256601B (zh) 2008-12-19 2009-12-18 塞尔托利细胞微胶囊化方法、所获得的微胶囊及其用于预防和治疗1型糖尿病的用途
NZ593507A NZ593507A (en) 2008-12-19 2009-12-18 A microencapsulation process of sertoli cells, microcapsules obtained and their use for prevention and cure of type 1 diabetes mellitus
EP09807677.1A EP2373299B1 (en) 2008-12-19 2009-12-18 A microencapsulation process of sertoli cells, microcapsules obtained and their use for prevention and cure of type 1 diabetes mellitus
AU2009329069A AU2009329069B2 (en) 2008-12-19 2009-12-18 A microencapsulation process of Sertoli cells, microcapsules obtained and their use for prevention and cure of Type 1 diabetes mellitus
PCT/IB2009/055847 WO2010070618A2 (en) 2008-12-19 2009-12-18 A microencapsulation process of sertoli cells, microcapsules obtained and their use for prevention and cure of type 1 diabetes mellitus
US13/140,728 US8865218B2 (en) 2008-12-19 2009-12-18 Microencapsulation process of sertoli cells, microcapsules obtained and use for treatment of type I diabetes mellitus
CA2756091A CA2756091C (en) 2008-12-19 2009-12-18 A microencapsulation process of sertoli cells, microcapsules obtained and their use for prevention and cure of type 1 diabetes mellitus
JP2011541709A JP5930279B2 (ja) 2008-12-19 2009-12-18 セルトリ細胞のマイクロカプセル化方法、得られるマイクロカプセルおよび１型糖尿病の予防および治療のためのその用途
KR1020117016882A KR101722476B1 (ko) 2008-12-19 2009-12-18 세르톨리 세포의 마이크로캡슐화 과정, 얻어진 마이크로캡슐, 및 제1형 당뇨병의 예방 및 치유를 위한 그것의 용도
RU2011128262/15A RU2598736C2 (ru) 2008-12-19 2009-12-18 Способ микроинкапсулирования клеток сертоли, получаемые микрокапсулы и их применение для предотвращения и лечения сахарного диабета 1 типа
IL213617A IL213617A (en) 2008-12-19 2011-06-16 Process of microsolation of Sertoli cell, received microcapsules and their use for the prevention or cure of type 1 diabetes mellitus
HK12104075.6A HK1163517A1 (en) 2008-12-19 2012-04-25 A microencapsulation process of sertoli cells, microcapsules obtained and their use for prevention and cure of type diabetes mellitus
US14/513,893 US20150044109A1 (en) 2008-12-19 2014-10-14 Microencapsulation process of sertoli cells, microcapsules obtained and use for treatment of type i diabetes mellitus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2008A000686A IT1392356B1 (it) 2008-12-19 2008-12-19 Procedimento di microincapsulamento di cellule del sertoli, microcapsule ottenute e loro impiego per la prevenzione e la cura del diabete mellito di tipo 1.

Publications (2)

Publication Number Publication Date
ITRM20080686A1 ITRM20080686A1 (it) 2010-06-20
IT1392356B1 true IT1392356B1 (it) 2012-02-28

Family

ID=40929607

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM2008A000686A IT1392356B1 (it) 2008-12-19 2008-12-19 Procedimento di microincapsulamento di cellule del sertoli, microcapsule ottenute e loro impiego per la prevenzione e la cura del diabete mellito di tipo 1.

Country Status (13)

Country Link
US (2) US8865218B2 (it)
EP (1) EP2373299B1 (it)
JP (1) JP5930279B2 (it)
KR (1) KR101722476B1 (it)
CN (1) CN102256601B (it)
AU (1) AU2009329069B2 (it)
CA (1) CA2756091C (it)
HK (1) HK1163517A1 (it)
IL (1) IL213617A (it)
IT (1) IT1392356B1 (it)
NZ (1) NZ593507A (it)
RU (1) RU2598736C2 (it)
WO (1) WO2010070618A2 (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140017304A1 (en) * 2011-03-29 2014-01-16 Myriam Bosmans Method for encapsulated therapeutic products and uses thereof
US9617517B2 (en) 2011-05-02 2017-04-11 National University Corporation Kumamoto University Small chemical compound which promotes induction of differentiation of stem cells into insulin-producing cells and method for inducing differentiation of stem cells into insulin-producing cells using said small chemical compound
US9839615B2 (en) * 2014-04-11 2017-12-12 Gary Harlem Clinical grade sodium alginate for microencapsulation of myofibroblasts isolated from wharton jelly for prevention and treatment of autoimmune and inflammatory diseases
CN105878030A (zh) * 2016-05-31 2016-08-24 江苏力凡胶囊有限公司 一种胶液放胶装置
RU2662173C1 (ru) * 2017-02-27 2018-07-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет" (ФГБОУ ВО "ВГУ") Способ получения частиц микрокапсулированного фенибута в альгинате натрия
CN109125806A (zh) * 2018-08-29 2019-01-04 广东克瑞斯普生物科技有限公司 一种皮下注射用干细胞微球凝胶复合物及其应用
US11096898B2 (en) * 2018-11-16 2021-08-24 GH Care Inc. Alginate microcapsules for cell and molecular therapy that secrete bioactive immune molecules
RU2751360C1 (ru) * 2020-11-05 2021-07-13 Федеральное государственное учреждение «Федеральный исследовательский центр «Фундаментальные основы биотехнологии» Российской академии наук» (ФИЦ Биотехнологии РАН) Способ получения биопрепаратов живых микроорганизмов с продленным сроком сохранения высокого титра жизнеспособных клеток

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956128A (en) 1984-05-25 1990-09-11 Connaught Laboratories Limited Droplet generation
JPH0628570B2 (ja) * 1986-02-13 1994-04-20 雪印乳業株式会社 カプセル体の製造方法及び装置
US5958404A (en) * 1994-04-13 1999-09-28 Research Corporation Technologies, Inc. Treatment methods for disease using co-localized cells and Sertoli cells obtained from a cell line
ES2272482T3 (es) * 2000-01-20 2007-05-01 Diabcell Pty Limited Preparacion y xenotransplante de islotes porcinos.
US7094045B2 (en) * 2003-12-09 2006-08-22 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microencapsulation system and method
US8603373B2 (en) * 2010-11-04 2013-12-10 Ricoh Company, Ltd. Method for producing particles, method for producing toner, and apparatus for producing particles

Also Published As

Publication number Publication date
ITRM20080686A1 (it) 2010-06-20
CA2756091A1 (en) 2010-06-24
US20150044109A1 (en) 2015-02-12
KR101722476B1 (ko) 2017-04-03
RU2598736C2 (ru) 2016-09-27
AU2009329069A1 (en) 2011-07-07
WO2010070618A3 (en) 2011-01-06
NZ593507A (en) 2013-02-22
AU2009329069B2 (en) 2016-09-01
CN102256601A (zh) 2011-11-23
IL213617A (en) 2016-05-31
EP2373299A2 (en) 2011-10-12
WO2010070618A2 (en) 2010-06-24
KR20110104067A (ko) 2011-09-21
US20110250280A1 (en) 2011-10-13
JP5930279B2 (ja) 2016-06-08
RU2011128262A (ru) 2013-01-27
US8865218B2 (en) 2014-10-21
CA2756091C (en) 2017-10-31
JP2012512866A (ja) 2012-06-07
IL213617A0 (en) 2011-07-31
HK1163517A1 (en) 2012-09-14
EP2373299B1 (en) 2017-03-22
CN102256601B (zh) 2014-10-29

Similar Documents

Publication Publication Date Title
IT1392356B1 (it) Procedimento di microincapsulamento di cellule del sertoli, microcapsule ottenute e loro impiego per la prevenzione e la cura del diabete mellito di tipo 1.
SMT201600216B (it) Ottaidropirrolo[3,4.c]pirroli disostituiti come modulatori del recettore di orexina
LTPA2019504I1 (lt) Pagerintos TM nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
CL2014002556A1 (es) Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.
CL2007002348A1 (es) Compuestos heterociclicos, moduladores de la actividad de la estearoil-coa-desaturasa; composicion farmaceutica, util para el tratamiento de enfermedades tales como diabetes, dislipidemias, obesidad, anorexia y acne.
CL2007003629A1 (es) Compuestos heterociclicos aril-sustituidos, moduladores del receptor de cannabinoides tipo i (cb1); proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos metabolicos y trastornos cognitivos.
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
CL2007003262A1 (es) Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades.
CL2013002505A1 (es) Composicion farmaceutica oral solida que comprende a) un nucleo de liberacion prolongada que contiene metformina, b) un recubrimiento sellador opcional, y c) un recubrimiento externo de liberacion inmediata que comprende a un agente activo, tal como un inhibidor de dpp-4 o de sglt-2; uso para tratar diabetes mellitus tipo 2.
CL2013003262A1 (es) Compuestos derivados de 1,3-oxazinas, con actividad inhibidora de bace 1 y/o bace2; composición farmacéutica que los comprende; procedimiento de preparación; uso en el tratamiento de la enfermedad de alzheimer, diabetes, trombosis arterial, cáncer, infarto al miocardio, entre otras patologías.
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
CL2008000791A1 (es) Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
JP2010527021A5 (it)
WO2009134973A8 (en) Quinolines and related analogs as sirtuin modulators
WO2011146518A3 (en) Pegylated c-peptide
WO2009012871A3 (de) Uv-filter-kapsel
BRPI1007350B8 (pt) compostos espiro heterocíclicos bicíclicos
BRPI0919796A2 (pt) formulação farmacêutica líquida livre de açúcar, e, excipiente líquido livre de açucar farmaceuticamente aceitável
ES2445846R1 (es) Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos
DE602006003935D1 (de) Verwendung von Stärke mit abgespaltenen Seitenketten in der Extrudierung / Spheronisierung von pharmazeutischen Pellets
CL2013001054A1 (es) Compuestos derivados de cianopirazoles, moduladores de la actividad del receptor gpr119 acoplado a la proteina g; composicion farmaceutica; y metodo para tratar una enfermedad, afeccion, o trastorno metabolico seleccionado de hiperlipidemia, diabetes tipo i, diabetes mellitus tipo ii, diabetes tipo i idiopatica, entre otras.
CL2008000596A1 (es) Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
WO2008147483A3 (en) Neurogenic compounds
CL2012000797A1 (es) Compuestos derivados de pirazol, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que los comprende; y su uso para el tratamiento de una enfermedad o condicion tal como sindrome metabolico, diabetes, resistencia a la insulina, complicaciones diabeticas y trastornos del peso corporal.